90Y-edotreotide for metastatic carcinoid refractory to octreotide. - Wikidata - awgldk - TriplyDB

90Y-edotreotide for metastatic carcinoid refractory to octreotide.

90Y-edotreotide for metastatic carcinoid refractory to octreotide.

http://www.wikidata.org/entity/Q34101554

about

Treatment of liver metastases in patients with neuroendocrine tumors of gastroesophageal and pancreatic origin ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes Targeted Delivery of Proteasome Inhibitors to Somatostatin-Receptor-Expressing Cancer Cells by Octreotide Conjugation Systematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumours New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours.Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis.Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature.Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapies New treatment options for patients with advanced neuroendocrine tumors.ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy.Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review.Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors.Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)A multimodal approach to the management of neuroendocrine tumour liver metastases A new era for the systemic therapy of neuroendocrine tumors.The Diagnosis and Treatment of Bronchopulmonary Carcinoid The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned Malignant neuroendocrine tumour of the gallbladder with elevated carcinoembryonic antigen: case report and literature review.Update on management of midgut neuroendocrine tumors.Nephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy.Pancreatic neuroendocrine tumors: biology, diagnosis,and treatment A woman with metastatic pancreatic neuroendocrine tumor.Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas.A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract.Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors Neuroendocrine neoplasms of the gut and pancreas: new insights.Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy.Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy.Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy.Yttrium-labelled peptides for therapy of NET.Radionuclide therapy beyond radioiodine.Treatment of liver metastases in patients with digestive neuroendocrine tumors.Inhibition of mTOR in carcinoid tumors.

P2860

Q21296729-F8984AE8-34BA-4239-A90A-0EF2E2DF8501 Q24603675-CF8BC4AC-7CBF-49B0-807C-1220DA0E77CC Q27702302-7AD36289-94B5-4FFA-91AB-B568041F7604 Q28071978-D2829CDC-4C65-4F6C-BF80-6B641A5D760F Q30364864-AA7A5B9F-F858-4FB9-8051-8F0DCF5F76F2 Q33392694-45D80671-80AF-488F-940B-4673CE16A6CB Q33435622-C5E3FA9A-A139-4E22-B2ED-B543F0CEDE91 Q33700134-D2ECE9F4-F152-48E5-A67A-8E8F07A27100 Q33737587-1EEB1D21-A9D2-4799-B12B-DAD842E547B7 Q33840177-8302F0E2-1322-42CD-AFDE-628C8736CCF8 Q34173336-6668525F-6091-42F6-8308-374826391B5C Q34248487-17367EC8-7077-4767-8ECF-AFB475B94189 Q34256413-825D39A9-59F3-4ED8-9175-C3C81E3549E1 Q34743520-ECEDE4C0-3946-4FAF-9FDB-B543F5B6E06B Q35371197-BBF608D8-B824-465D-95A7-DCAD226AE631 Q35675435-D7AC7322-1D6C-4277-95B3-D395219846EC Q35738251-C36669A6-3C8C-463A-A905-9EA6B2D1E45C Q35760798-49659018-4F57-4C98-AAC2-239AB022F90B Q35810562-5205C8F6-F090-47B3-88DA-9ADD2D5FB9F8 Q35863865-83388843-9EA9-4CE5-81BB-F58F3B486380 Q35916386-B9355161-1308-4836-9894-CD824580C8B7 Q36755905-B98C7170-8FF9-4595-83E3-DB969B23252E Q36849357-92AF7385-E4CA-4444-94BE-6DCB32AFB5F2 Q36871673-7B77985D-1A91-4E87-A769-56CA8F40B38B Q36893968-877C1D03-7311-4F56-91F9-EC1544BC53C5 Q37025143-3B6187DE-3573-4F6C-A5D0-DC8258086041 Q37167160-59313867-9B5C-4D39-A3F9-68691AD51C3A Q37354131-1745C484-EF9D-4C6B-9449-F9AFEB52B486 Q37584857-C9B0BADD-65E9-44B4-A70D-ADEA830DCCE6 Q37624511-C5A54A0F-22EA-4B89-967D-509AD92C0E5B Q37859615-3CEADD39-9516-4B33-8781-101797915262 Q37889407-02AE46AE-F05B-4279-9DB5-BE071ED54E7C Q37909911-C6309322-8D19-493A-A367-B4E26EFE1229 Q37962416-486759FE-6299-4737-9462-FCF7AD05F180 Q37975101-6B03994A-14A1-48CD-9830-7FEE920A32A7 Q37981893-097DDCD6-EEFA-4628-AFEF-7F2C659D6778 Q37990401-59C30B23-0424-4DE7-8037-527B117A0984 Q38027798-85156A5B-02BF-4796-BB18-D01FDA400487 Q38029275-EA3C0FFB-19EF-455E-982F-B4A5A4D3FACE Q38034141-672C8952-87B1-4691-8A42-B2F95613ECA4

P2860

90Y-edotreotide for metastatic carcinoid refractory to octreotide.

http://www.wikidata.org/entity/Q34101554

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

90Y-edotreotide for metastatic carcinoid refractory to octreotide.

@ast

90Y-edotreotide for metastatic carcinoid refractory to octreotide.

@en

90Y-edotreotide for metastatic carcinoid refractory to octreotide.

@nl

type

label

90Y-edotreotide for metastatic carcinoid refractory to octreotide.

@ast

90Y-edotreotide for metastatic carcinoid refractory to octreotide.

@en

90Y-edotreotide for metastatic carcinoid refractory to octreotide.

@nl

prefLabel

90Y-edotreotide for metastatic carcinoid refractory to octreotide.

@ast

90Y-edotreotide for metastatic carcinoid refractory to octreotide.

@en

90Y-edotreotide for metastatic carcinoid refractory to octreotide.

@nl

P1433

Q34101554-7FF89DA9-E426-4475-BC48-C8C043253BF6

P1476

Q34101554-FCD86F18-9773-4E60-8272-AAAC91043DE0

P2093

Q34101554-060F7C7C-F2D0-42E0-9F8F-5082445E0CB3

Q34101554-1273E333-20EE-4369-82B1-46213A7DCE52

Q34101554-18C28C96-10C7-4785-B89A-4F62B4115A6F

Q34101554-2CE38B09-25EC-4BA6-942A-EF6FE0AB88E4

Q34101554-3B5CDD2D-9A09-4BBC-AEDE-DA6B00FF5576

Q34101554-42DB9263-0D6E-482A-ADE3-227AA1AEDBD3

Q34101554-6AA9AB89-4C9E-43F8-AC43-7E53FAA45830

Q34101554-C0190FF6-92FE-4B08-AA1F-1A8B27A3CABD

Q34101554-E4725371-2169-4642-8458-27DAADD55D8D

Q34101554-F3EC8FDB-32F0-4FF1-BC76-A9A9DC6C2D10

P2860

Q34101554-07F15ECF-A33E-4370-B536-DE9F32DEEB12

Q34101554-0BD114A4-62F4-4DFE-B48B-103B8AFE81D9

Q34101554-0ECE2E6A-CE0D-4E8B-9CB4-306CB9BCE968

Q34101554-10FE2498-466A-4188-AE06-6C67B9616DC9

Q34101554-20E28BE7-DD92-4938-B265-1A32D72E3D35

Q34101554-26170D8C-0D44-44ED-A2E1-C2FA1C2681F1

Q34101554-2CE4CE79-8915-462C-BBDA-AEFCB5DD9ECC

Q34101554-4D36C8FA-993B-4501-B864-624086A7C501

Q34101554-505B5BFC-4496-48B5-919C-119CDD560AC9

Q34101554-54C7873C-1963-445C-8439-4B0CC1795BDE

P304

Q34101554-168C6297-CC50-4217-B91C-FA2419E48BCC

P31

Q34101554-03723B1C-8295-407C-AC00-11E49831F683

P356

Q34101554-3FA9EE69-D088-4F54-869C-EA7D18DDF11C

P407

Q34101554-DDC2A5FD-E38B-4397-9020-D634C77B1B21

P433

Q34101554-3C532BA0-B78F-4D98-B3EA-80A5F5FF3742

P478

Q34101554-89D76681-98DF-416D-82A9-C18B979731B0

P50

Q34101554-1DD0EE50-E976-40CB-AB63-84148A7E1DB0

Q34101554-48042536-B4A7-4109-922B-3E89E9E35C0C

Q34101554-58A7E974-353C-4A74-A611-B2BE95980F2E

Q34101554-7D546B15-A2D9-44A5-9BD6-04E20CBF3718

Q34101554-98850C10-91B6-4715-AD30-D4176A4CBC9A

Q34101554-A3539894-9FDA-418D-81B2-EAB7417549E2

Q34101554-AF27615A-DE48-44C5-ABA3-D991C8BD4F1F

Q34101554-E46FC44C-B929-438C-A321-467347E138B9

Q34101554-F0BE564D-B283-450E-A3D5-DDE478FCDA9B

P577

Q34101554-26B0B425-BD17-470A-8B26-ECF60A11299E

P698

Q34101554-910D2262-74D1-4F1E-99B7-0FC28796B95B

P932

Q34101554-B9937650-752D-4C84-9BDC-027DE6316966

P356

JCO.2009.22.8585

P1433

Journal of Clinical Oncology

P1476

90Y-edotreotide for metastatic carcinoid refractory to octreotide.

@en

P2093

Al B Benson

http://www.w3.org/2001/XMLSchema#string

Ashley B Grossman

http://www.w3.org/2001/XMLSchema#string

Jean-Louis Baulieu

http://www.w3.org/2001/XMLSchema#string

Katherine A Kacena

http://www.w3.org/2001/XMLSchema#string

Kjell Oberg

http://www.w3.org/2001/XMLSchema#string

Lowell Anthony

http://www.w3.org/2001/XMLSchema#string

Mary Connolly

http://www.w3.org/2001/XMLSchema#string

Norman LaFrance

http://www.w3.org/2001/XMLSchema#string

Stanislas A Pauwels

http://www.w3.org/2001/XMLSchema#string

Yong Li

http://www.w3.org/2001/XMLSchema#string

P2860

Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment.

Chemotherapy in the treatment of neuroendocrine malignant tumors.

A 5-decade analysis of 13,715 carcinoid tumors.

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.

Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine.

Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.

Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.

Updated population-based review of carcinoid tumors.

Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.

Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial.

P304

1652-1659

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.22.8585

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Eric Van Cutsem

Rodney J. Hicks

Thomas O'Dorisio

Francoise Borson-Chazot

M Sue O'Dorisio

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20194865

http://www.w3.org/2001/XMLSchema#string

P932

4872330

http://www.w3.org/2001/XMLSchema#string